The role of cytoreduction in metastatic prostate cancer (mPC) is largely experimental in humans, but murine models suggest reduced metastatic disease progression, reduced prostate specific antigen (PSA) velocity, and perhaps prolonged survival [4, 5]. The gene discussed is KLK3; the disease is metastatic prostate carcinoma.